{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Ondansetron in Alcohol Use Disorder: A Systematic Review\n",
    "\n",
    "**A presentation of the main findings**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## The Problem: Alcohol Use Disorder (AUD)\n",
    "\n",
    "- A complex, chronic condition with significant global impact.\n",
    "- Existing treatments have variable efficacy, highlighting the need for personalized medicine."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## A Potential Solution: Ondansetron\n",
    "\n",
    "- A selective 5-HT3 receptor antagonist.\n",
    "- Shows promise in reducing alcohol consumption and craving, particularly in specific patient subgroups."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Methods: A Systematic Review\n",
    "\n",
    "We conducted a systematic review of the literature to evaluate the efficacy of ondansetron for AUD.\n",
    "\n",
    "- **Databases Searched:** Pubmed, Wiley Online Library, Psychinfo, and Cochrane.\n",
    "- **Inclusion Criteria:** Peer-reviewed studies examining ondansetron's effects in individuals with AUD.\n",
    "- **Studies Included:** 19 clinical trials were analyzed."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Key Findings: Alcohol Use Reduction\n",
    "\n",
    "Ondansetron demonstrated effectiveness in reducing alcohol consumption, but this effect was most pronounced in specific subgroups:"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Early-Onset Alcoholism (EOA)\n",
    "\n",
    "- Patients who developed AUD at a younger age showed a significant reduction in:\n",
    "  - Drinks per day\n",
    "  - Drinks per drinking day\n",
    "  - An increase in the percentage of days abstinent"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Specific Genotypes\n",
    "\n",
    "- Individuals with the **LL genotype** in the 5-HTT gene showed a greater reduction in alcohol consumption.\n",
    "- Other genetic markers in the HTR3A and HTR3B genes also predicted a better response to ondansetron."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Key Findings: Craving and Mood\n",
    "\n",
    "- **Craving:** Ondansetron significantly reduced craving, especially in early-onset alcoholics.\n",
    "- **Mood:** Ondansetron also showed a positive effect on mood disturbances in some studies."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Predictors of Treatment Outcome\n",
    "\n",
    "- **Typologies:** The Early-Onset/Late-Onset Alcoholism (EOA/LOA) typology was a better predictor of treatment response than the Type A/B typology.\n",
    "- **Biomarkers:** 5'HTTPLR mRNA levels show promise as a biomarker for treatment effectiveness in individuals with the LL genotype."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Conclusion\n",
    "\n",
    "- Ondansetron is a promising medication for AUD, but its efficacy is largely dependent on patient characteristics.\n",
    "- **Personalized medicine is key:** Identifying the right patients through clinical evaluation (age of onset) and genotyping is crucial for successful treatment.\n",
    "- **Future Research:** Larger, long-term studies with broader inclusion criteria are needed to confirm these findings and further explore the potential of ondansetron in treating AUD."
   ]
  }
 ],
 "metadata": {},
 "nbformat": 4,
 "nbformat_minor": 5
}